Evidence map›Paper›PMID 40211809›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

CNPY2 Aggravates Renal Tubular Cell Ferroptosis in Diabetic Nephropathy by Regulating PERK/ATF4/CHAC1 Pathway and MAM Integrity.

Jingfang Chen, Dongwei Liu, Lei Lei, Ting Liu, Shaokang Pan, Hui Wang, Yong Liu, Yingjin Qiao, Zhangsuo Liu, Qi Feng

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingfang ChenDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Dongwei LiuDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Lei LeiDepartment of Cardiology, Henan Provincial Chest Hospital, Chest Hospital of Zhengzhou University, Zhengzhou, 450003, P. R. China.
Ting LiuDepartment of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Shaokang PanDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Hui WangDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Yong LiuDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Yingjin QiaoDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.
Zhangsuo LiuDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.ORCID https://orcid.org/0000-0002-2916-8371
Qi FengDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Research Institute of Nephrology, Zhengzhou University, Traditional Chinese Medicine Integrated Department of Nephrology,the First Affiliated Hospital of Zhengzhou University, Henan Province Research Center for Kidney Disease,the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China.

Funding

Excellent Young Scientists Fund Program of the Natural Science Foundation of Henan Province 252300421112Higher Education Key Research Project of Henan Province 24A320021Key R&D and Promotion Special Projects of Henan Province 242102310009National Natural Science Foundation of China Joint Project U21A20348National Natural Science Young Scientists Foundation of China 82200796Scientific and Technological Innovation Young Top Talents in Central PlainsYoung and Middle-aged Innovation Talents of Health Science and Technology Project in Henan Province YQRC2024011Youth Talent Promotion Project of Henan Province 2024HYTP046
6 · The paper itself

Abstract

Ferroptosis is emerging as a novel mechanism for understanding renal tubular injury in diabetic nephropathy (DN). The mitochondria-associated endoplasmic reticulum membrane (MAM) plays a crucial role in the regulation of numerous cellular processes, including mitochondrial dysfunction and endoplasmic reticulum (ER) stress (ERS). However, the exact mechanism underlying ferroptosis and MAM in DN remains unclear. In this study, we identified that canopy FGF signaling regulator 2 (CNPY2) is upregulated in the renal tubules of DN. Downregulation of CNPY2 alleviated ferroptosis and improved MAM integrity in the renal tubular epithelial cells of db/db mice. Conversely, CNPY2 overexpression aggravated tubular injury in DN by accelerating ferroptosis and disrupting MAM formation. Mechanistically, CNPY2 activated the PERK/ATF4/CHAC1 signaling pathway to facilitate ferroptosis, thus contributing to tubular injury in DN. These findings highlight the critical role of CNPY2 in modulating ferroptosis and MAM formation in DN progression, and suggest that CNPY2 is a feasible therapeutic target for DN.

Indexed as

Activating Transcription Factor 4Diabetic NephropathieseIF-2 KinaseFerroptosisKidney TubulesAnimalsDisease Models, AnimalEndoplasmic ReticulumEndoplasmic Reticulum StressHumansMaleMiceMice, Inbred C57BLMitochondriaSignal TransductionActivating Transcription Factor 4Atf4 protein, mouseeIF-2 Kinasecanopy FGF signaling regulator 2 (CNPY2)diabetic nephropathyendoplasmic reticulum (ER) stressferroptosismitochondria‐associated endoplasmic reticulum membrane (MAM)

Identifiers

PMID40211809
PMCPMC12224942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.